Abstracts tagged "Biomarkers"

Abstract Number: 0869 • ACR Convergence 2023
Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis
Irene Lorenzo Gomez¹, Uxía nogueira Recalde², Christian García Domínguez¹, Natividad Oreiro Villar³, Jose Antonio Pinto Tasende³, Mohit Kapoor⁴, Francisco J. Blanco³ and Beatriz Carames¹, ¹Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (iNIBIC), A Coruña, Spain, ²Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁴Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Defects in homeostatic mechanisms, such as autophagy, contribute to joint aging and Osteoarthritis (OA) and precede joint damage (1). OA is a complex and…
Abstract Number: 1171 • ACR Convergence 2023
Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies
Caoilfhionn M. Connolly¹, Jana Lovell², Melody Chung³, Brittany Adler², Jemima Albayda², Eleni Tiniakou², Christopher Mecoli¹, Stefan Zimmerman², Lisa Christopher-Stine², Nisha Gilotra² and Julie Paik², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Kaiser Permanante, Baltimore, MD
Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
Abstract Number: 1461 • ACR Convergence 2023
Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL
Michelle Barraclough¹, Carolina Munoz-Grajales², Lauren Erdman³, Juan Pablo Diaz Martinez⁴, Kathleen Bingham¹, Mahta Kakvan⁵, Roberta Kretzmann⁶, Carmela Tartaglia⁷, Lesley Ruttan⁸, May Choi⁹, Simone Appenzeller¹⁰, Sherief Marzouk⁶, Dennisse Bonilla⁴, Patti Katz¹¹, Dorcas Beaton¹², Anna Goldenberg¹³, Robin Green⁶, Joan Wither¹ and Zahi Touma⁶, ¹University Health Network, Toronto, ON, Canada, ²UHN/TWH, Toronto, ON, Canada, ³Hospital for SickKids, Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of California San Francisco, San Rafael, CA, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Hospital for SickKids, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with SLE [prevalence of 38% (range: 20%-80%)]. The exact mechanisms underlying CI is complex and multifactorial.…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 1887 • ACR Convergence 2023
Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Dario Mazza¹, Siba Raychaudhuri², Yasser Abdelhafez¹ and Abhijit Chaudhari³, ¹University of California Davis, Sacramento, CA, ²UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ³UC Davis School of Medicine, Sacramento, CA
Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…
Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 2389 • ACR Convergence 2023
Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Matthias Froehlich¹, Marc Schmalzing², Hannah Labinsky³, Jan Portegys³, Ottar Gadeholt⁴, Patrick-Pascal Strunz¹, Eva C. Schwaneck⁵, Marcus Dittrich⁶, Tobias Mueller⁷ and Michael Gernert³, ¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, ²University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ³Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatologische Schwerpunktpraxis Würzburg, Würzburg, Germany, ⁵MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH, Hamburg, Germany, ⁶Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Germany ; Institute for Human Genetics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany, ⁷Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany
Background/Purpose: Monitoring disease activity in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) remains challenging as standard inflammation parameters, i.e., C-reactive protein (CRP) and erythrocyte…
Abstract Number: 0168 • ACR Convergence 2023
What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
Nick Bansback¹, Alex Tam², Dafna Gladman³, Vathany Kulasingam⁴, Eldon Spackman⁵ and Vinod Chandran⁶, ¹University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Initiating treatment in patients with psoriasis (PsO) who have unrecognized Psoriatic arthritis (PsA) may slow disease progression and improve long-term outcomes. Several candidate biomarkers…
Abstract Number: 0557 • ACR Convergence 2023
Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE
Jennifer Rogers¹, Amanda Eudy², Daniel Wojdyla³, Tyler O'Malley⁴, David Pisetsky⁵, Roberta Alexander⁴, Kai Sun¹, Lisa Criscione-Schreiber⁶, Jayanth Doss¹, Rebecca Sadun¹, Mithu Maheswaranathan⁶ and Megan Clowse⁷, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Exagen, Vista, CA, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University, Chapel Hill, NC
Background/Purpose: Cell-bound complement activation products (CB-CAPs), when part of a multi-analyte assay with algorithm (MAP), are valuable SLE diagnostic biomarkers. Levels of erythrocyte-bound complement activation…
Abstract Number: 0676 • ACR Convergence 2023
Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center
Takashi Yamane¹ and Akira Hashiramoto², ¹Kakogawa Central City Hospital, Kakogawa, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with eosinophil infiltration and Anti-neutrophil cytoplasmic antibody (ANCA) production. Mepolizumab (MPZ), an anti-IL-5 monoclonal…
Abstract Number: 0884 • ACR Convergence 2023
Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis
Shady Younis, Audrey Bai, heidi Wong, Zelda Love, Qian Wang and William Robinson, Stanford School of Medicine, Stanford, CA
Background/Purpose: Mast cells in the osteoarthritis (OA) synovium correlate with disease severity. This study aimed to further elucidate the role of mast cells in OA…
Abstract Number: 1184 • ACR Convergence 2023
A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker
Deepak Kumar¹, Lukas Adamowicz², Benjamin Senderling¹, Mary Gheller¹, Michael LaValley³, Kathryn Bacon¹, Pirinka Georgiev², Charmaine Demanuele², Paul Wacnik² and Tuhina Neogi⁴, ¹Boston University, Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this study in people with knee osteoarthritis (OA) were to (a) examine the agreement between measures of gait and chair stand…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1716 • ACR Convergence 2023
High-Throughput Semi-Automated Micro-CT Analysis Identifies the Cuboid Bone as a Sex-Dependent Biomarker of Inflammatory-Erosive Arthritis in TNF-Tg Mice
H. Mark Kenney¹, Kiana Chen², Lindsay Schnur³, Jeffrey Fox³, Ronald Wood³, Lianping Xing⁴, Christopher T Ritchlin⁵, Homaira Rahimi⁶, Edward Schwarz⁶ and Hani Awad³, ¹University of Rochester School of Medicine and Dentistry, Henrietta, NY, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ⁶University of Rochester, Rochester, NY
Background/Purpose: Development of reliable disease activity biomarkers is critical for diagnostics, prognostics, and novel drug development. In the case of preclinical models of inflammatory-erosive arthritis,…
Abstract Number: 1984 • ACR Convergence 2023
Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis
Mukesh Ahuja¹, Donna Skerrett², Curtis Gravance³, Divya Navuru⁴, Ravi Krishnan⁵, Charles Inderjeeth⁶, Philip Bloom⁷ and Schnitzer Thomas⁸, ¹Paradigm Biopharmaceuticals, Oak Brook, IL, ²Paradigm Biopharmaceuticals, New York, NY, ³Paradigm Biopharmaceuticals, Melba, ID, ⁴Paradigm Biopharmaceuticals, Melbourne, Australia, ⁵Paradigm Biopharmaceuticals, Adelaide, Australia, ⁶University of Western Australia / Linear Clinical Research, Perth, Australia, ⁷Sportsmed Biologic, Melbourne, Australia, ⁸Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is an inflammatory joint disease, causing chronic pain, disability, and reduced quality of life. Affected joints may include the knee, hip, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].